Needham Maintains Buy Rating on Revolution Medicines Despite Wider Q1 Loss

Needham has kept its 'Buy' rating for Revolution Medicines (RVMD) despite the company reporting a wider-than-expected loss in Q1 2026. The firm lowered its price target to $183 from $186, citing increased operating and R&D costs as key factors behind the shortfall.

By Sheryar Siddiq Wed, May 20, 2026 at 10:22 AM GMT+3 2 min read · Yahoo Finance · May 20, 2026, 07:22 UTC

Needham Maintains Buy Rating on Revolution Medicines Despite Wider Q1 Loss

Tickers: $RVMD

Topics: analyst ratings biotech financial performance pharmaceuticals

Read the full article at Yahoo Finance

More World news

Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC
AIRO Group Holdings Reaffirms 2026 Revenue Growth Guidance Amid $200 Million Drone Backlog Seeking Alpha · November 12, 2026, 18:40 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC